U.S. pharma large copyright scrapped two experimental weight loss products previous calendar year—a after-each day capsule, lotiglipron, due to elevated liver enzymes in addition to a twice-day by day pill, danuglipron, as a result of robust Unwanted effects—but CEO Albert Bourla has